Lee PY, Day-Lewis M, Henderson LA, et al. - A dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C) can complicate pediatric SARS–CoV-2 infection. Researchers here studied the clinical and immunologic spectrum of MIS-C and its correlation with other inflammatory conditions of childhood. In this retrospective study, they studied 28 patients who fulfilled the case definition of MIS-C and presented between March 2020 and June 2020. Laboratory confirmation of SARS–CoV-2 infection was reported in all these patients. The patients commonly, but not ubiquitously, had lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels. MIS-C was distinguished from KD by cytopenias and MIS-C differed from MAS in terms of the degree of hyperferritinemia and pattern of cytokine production. Patients with MIS-C were administered immunomodulatory therapy including intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). All cases, including 6 cases that did not require immunomodulatory therapy, exhibited clinical and laboratory improvement. Per these findings, MIS-C involves a broad phenotypic spectrum with clinical and laboratory features different from KD and MAS.